Tag Archives: blockbuster drugs

  • Pharmaceutical Consultants-The Key to a Rapidly Changing Industry

    … from all sides, particularly through the impact of new technologies across the whole discovery and development process and from changes in the way that health care is funded and delivered.” The changes Peakman spoke of have progressed even further, and there are other, more radical changes than those he had in mind in 2000. Growing FDA intrusion and compliance burdens, a dwindling number of blockbuster drugs and looming patent expirations, slowing growth in the market and shrinking profit …

  • Lean Manufacturing Solves Drug Recalls and Bad Press

    … new blockbuster drugs, and the cost of bringing new drugs to market running in the neighborhood of $1.5 billion, drug companies are struggling. The opportunity for them to benefit from a new image and from lean manufacturing implementation is at hand. Lean manufacturing techniques do work, but effective implementation in the pharmaceutical industry requires knowledge of the special circumstances that exist in the industry, i.e. the difficulties involved in altering batch sizes, the fact that …

  • Lean Manufacturing for the Competitive Edge

    Factors within the pharmaceutical industry have combined with economy-related issues to force pharmaceutical companies to seek new ways of maintaining or regaining their competitive edge.  Increasing globalization, scarcity of new blockbuster drugs, growing regulatory burdens, the failing we-are-different attitude, and a longstanding emphasis on R&D at the expense of production are all making it necessary for pharmaceutical manufacturers to strive for lower costs, increased efficiency and …

  • The Smart Road to Pharmaceutical Consulting

    Expenses surrounding R&D, production, regulatory compliance, marketing, and product distribution continue to increase. The cost of medication and various kinds of specialized health services continue to rise. In addition, the number of blockbuster drugs is dwindling, safety concerns are growing, and greater government intervention looms. All of this means that the value of and the return on investment for pharmaceutical consulting services are also increasing. Staying competitive and …

  • The Benefits of Using Pharmaceutical Consultants

    … violation is attached to this bill. According to informed pharmaceutical consultancy experts, this is very likely an alarming harbinger of additional, widespread legislation of the same cost-increasing kind. Then there are the generic drugs, which had boasted double-digit growth until very recently. In 2008 the rate of sales growth for generics had slowed to 3.6% from 11.4% year-over-year. While some of this decline can be attributed to less patent expirations for blockbuster drugs, much of it …

  • How a Pharmaceutical Consultant Can Improve Business Health

    No doubt, things are tough—and getting tougher—for the pharmaceutical industry today, especially for the smaller companies. They now have to buckle down and find ways to operate far more efficiently than in easier times. Every drop of value has to be squeezed out of every dollar invested in R&D, production, distribution, marketing, and sales. And this is where pharmaceutical consultants can help.

  • Is the Pharmaceutical Industry Going Green?

    … pharmaceutical companies such as Johnson and Johnson, and Pfizer, are taking drastic steps all across the board, to cut spending, and one of them is an adoption of green manufacturing, known as green chemistry. With the pharmaceutical industry facing looming expiring patents of some of their biggest blockbuster drugs, as well as the proper candidates to replace them, uncertainty looms in the pharmaceutical industry.  Because of this economic uncertainty in the pharmaceutical industry, many …

  • Emerging Trends in the Pharmaceutical Industry

    … Many life sciences consulting firms are pointing out, that as patents held to key drugs begin to expire in the next ten years, it could hurt the growth of the North American pharmaceutical market.  Coupled with the growing prevalence of generic drugs all over the world, as well as dwindling drug pipelines, and the development of less blockbuster drugs and less and less economic cooperation, these factors may challenge the growth of the global marketplace in times to come.  Only time will tell. …

  • Lean Six Sigma and Process Excellence to the Rescue

    The Pharma industry is facing extreme change.  Gone are the days when pharmaceutical manufacturers made million in profits no matter the times.  Today’s challenges are transmuting the field’s reality for the future: expiration of blockbuster drug patents, a decreasing pipeline of blockbuster drugs, pressure from generics, doubt about the future of healthcare compensation, mergers and acquisitions. This somber panorama is moving Pharmas to evaluate the best ways to combine and …

  • Universal Healthcare And Drug Company Revenues

    Could the end of blockbuster drugs be a reality? Back in the 1990’s we saw many new drugs come to the market that seemed to be created to be mass-marketed directly to the public – in spite of the fact that they were prescription drugs. These drugs, in their majority, were designed to treat on-going conditions. The pharmaceutical industry’s focus switched toward the creation of drugs geared toward the treatment of conditions that require said treatment for a long time – perhaps lifelong. …